|
|
Volumn 22, Issue 2, 2008, Pages
|
|
Preface
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANDROGEN RECEPTOR;
ANDROSTANOLONE;
ANTIANDROGEN;
DUTASTERIDE;
FINASTERIDE;
PRASTERONE;
PROSTATE SPECIFIC ANTIGEN;
STEROID 5ALPHA REDUCTASE INHIBITOR;
TESTOSTERONE;
ANDROGEN;
ADJUVANT THERAPY;
ADVANCED CANCER;
ANDROGEN BLOOD LEVEL;
CANCER CELL;
CANCER GROWTH;
CANCER LOCALIZATION;
CANCER MORTALITY;
CANCER STAGING;
CANCER SURVIVAL;
CELL PROLIFERATION;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG POTENCY;
DRUG TREATMENT FAILURE;
EARLY INTERVENTION;
EDITORIAL;
HORMONE ACTION;
HORMONE INHIBITION;
HUMAN;
METASTASIS POTENTIAL;
MONOTHERAPY;
PROGNOSIS;
PROSTATE CANCER;
PROSTATIC INTRAEPITHELIAL NEOPLASIA;
ENDOCRINE SYSTEM;
ENDOCRINOLOGY;
MALE;
METABOLISM;
PATHOPHYSIOLOGY;
PHYSIOLOGY;
PROSTATE;
PROSTATE TUMOR;
ANDROGENS;
ENDOCRINE SYSTEM;
ENDOCRINOLOGY;
HUMANS;
MALE;
PROSTATE;
PROSTATIC NEOPLASMS;
|
|
EID: 42949125893
PISSN: 1521690X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.beem.2008.02.005 Document Type: Editorial |
|
Times cited : (5)
|
|
References (8)
|
